<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250301064887N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-08-10</date_registration>
      <primary_sponsor>The University of Mohaghegh Ardabili</primary_sponsor>
      <public_title>The Effect of Transdiagnostic Cognitive‑Behavioral Therapy on Improving Posttraumatic Stress Disorder in Veterans</public_title>
      <acronym></acronym>
      <scientific_title>Moderating Effects of Trauma Severity and Comorbid Major Depression on the Efficacy of Transdiagnostic Cognitive‑Behavioral Therapy for Clinical Symptoms and Emotional Indicators in Veterans with Posttraumatic Stress Disorder: A Randomized Controlled Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>https://irct.ir/trial/91629</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomization will be performed using the online Sealed Envelope randomization service. Given the total sample size of 60 participants and the presence of two study arms (intervention and control), block sizes will be selected as multiples of two (i.e., blocks of 2 and 4). Based on the generated randomization sequence and the predefined allocation codes, participants will be assigned to either the intervention group (A) or the control group (B), Blinding description: The study will employ a double-blind design, in which both the participants and the outcome assessors will be blinded to study group allocation. Participants will not be informed of their assigned treatment group and will receive only general information regarding the overall objectives of the study. Likewise, the outcome assessors will remain blinded to group allocation throughout the study.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Post-Traumatic Stress Disorder.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: transdiagnostic cognitive-behavioral therapy. For this group, the transdiagnostic cognitive-behavioral therapy of Barlow et al. (2017) will be used. This intervention will include 10 individual treatment sessions, each of which will last 90 minutes. Specifically, the goal of this protocol is reducing the intensity and frequency of negative emotions. Unified protocol is designed to accomplish this goal through emotion-focused education, awareness techniques, cognitive strategies, problem-solving and an array of behavioral strategies, including a full-range of exposure and activation techniques. Intervention 2: Control group: The group awaiting transdiagnostic cognitive-behavioral therapy. After the intervention group sessions are completed, transdiagnostic cognitive-behavioral therapy will be implemented as in intervention group number one.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
In general, personal information about participants' data is not shared. Rather, some of the information related to the main outcome of the study, namely the results of the participants' statistical data, is published.

When:
Access period starts 6 months after results are published.

To whom:
In general, researchers working in academic and scientific institutions, students, and professors are allowed to apply, and others are also allowed to apply, provided that ethical considerations are observed.

Conditions:
In general, scientific research documentation is provided to university employees, professors, and students for the exchange of scientific information, but personal data is not provided to others due to compliance with professional ethics in research and non-abuse.

Where to obtain:
Applicants must contact the researcher via email to receive documents and data. Researcher's details and email address" First and last name: Sanaz Eyni Email address: s.eyni@uok.ac.ir

How to obtain:
First, the applicant must send an email to the researcher, and depending on the applicant's circumstances, a scientific commitment letter is obtained from the applicant to comply with professional ethics and avoid abuse, and then the research documentation and data are provided to the applicant.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sanaz Eyni</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Humanities and Social Sciences., university of Kurdistan., Pasdaran Blvd</address>
        <city>Sanandaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6617715175</zip>
        <telephone>+98 87 3366 0077</telephone>
        <email>s.eyni@uok.ac.ir</email>
        <affiliation>The University of Kurdistan</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sanaz Eyni</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Humanities and Social Sciences., university of Kurdistan., Pasdaran Blvd</address>
        <city>Sanandaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6617715175</zip>
        <telephone>+98 87 3366 0077</telephone>
        <email>s.eyni@uok.ac.ir</email>
        <affiliation>The University of Kurdistan</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>A diagnosis of PTSD established by a psychiatrist based on the Structured Clinical Interview for DSM-5 (SCID-5)
A score greater than 33 on the Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)
Stable psychotropic medication use during the previous three months
Provision of written informed consent to participate in the treatment sessions</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>60 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>Current psychotic disorder or substance use disorder
Concurrent participation in another form of psychotherapy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F43.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Post-traumatic stress disorder (PTSD)</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: transdiagnostic cognitive-behavioral therapy. For this group, the transdiagnostic cognitive-behavioral therapy of Barlow et al. (2017) will be used. This intervention will include 10 individual treatment sessions, each of which will last 90 minutes. Specifically, the goal of this protocol is reducing the intensity and frequency of negative emotions. Unified protocol is designed to accomplish this goal through emotion-focused education, awareness techniques, cognitive strategies, problem-solving and an array of behavioral strategies, including a full-range of exposure and activation techniques.</i_keyword>
      <i_keyword>Control group: The group awaiting transdiagnostic cognitive-behavioral therapy. After the intervention group sessions are completed, transdiagnostic cognitive-behavioral therapy will be implemented as in intervention group number one.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Post-traumatic stress disorder score. Timepoint: Measuring the post-traumatic stress disorder before the intervention, after the intervention, three and six months after the end of the intervention. Method of measurement: Post-traumatic stress disorder scale.</prim_outcome>
      <prim_outcome>Major depression score. Timepoint: Measurement of major depression before the intervention, after the intervention, three and six months after the end of the intervention. Method of measurement: Beck depression inventory.</prim_outcome>
      <prim_outcome>Trauma severity score. Timepoint: Measurement of trauma severity before intervention, after intervention, three and six months after the end of intervention. Method of measurement: Harvard trauma questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Emotion regulation score. Timepoint: Measurement of emotion regulation before the intervention, after the intervention, three and six months after the end of the intervention. Method of measurement: Difficulties in emotion regulation scale.</sec_outcome>
      <sec_outcome>Experiential avoidance score. Timepoint: Measurement of experiential avoidance before the intervention, after the intervention, three and six months after the end of the intervention. Method of measurement: Acceptance and action questionnaire.</sec_outcome>
      <sec_outcome>Emotional reactivity score. Timepoint: Measurement of emotional reactivity before the intervention, after the intervention, three and six months after the end of the intervention. Method of measurement: Emotional reactivity scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>The University of Mohaghegh Ardabili</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-07-01</approval_date>
        <contact_name>Research Ethics Committees of University of Mohaghegh Ardabili</contact_name>
        <contact_address>University of Mohaghegh Ardabili, the end of University Street Ardabil Ardabil Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
